ImmunoGen Ovarian Cancer Drug Reaches BLA Milestone

Massachusetts-based ImmunoGen announced that it has submitted a biologics license application (BLA) to the U.S. Food and Drug Administration for mirvetuximab soravtansine to treat ovarian cancer. The BLA is one of several positive milestones ImmunoGen, a clinical-stage biotechnology company focused on developing antibody-drug conjugate (ADC) therapeutics for cancer, has reached in its ovarian cancer research.